Group items tagged

Dementia and Alzheimer's disease remained the leading cause of death in England and Wales in 2023, maintaining the pre-pandemic trend, according to the latest data from the Office for National Statistics (ONS). The figures reveal that there were 66,876 deaths with an underlying cause of dementia and Alzheimer's disease, accounting for 11.6% of all deaths registered that year. In response to this growing health concern, Luye Pharma is hosting a free special educational webinar on 6 November 2024 (timing: 18:30 - 20:00) for healthcare professionals. Titled "Treating Dementia in 2024: Optimising Pathways Between Primary and Secondary Care," the online session will focus on addressing the ever-increasing challenges in dementia treatment and how to optimise pathways between primary and secondary care. The webinar will feature expert speakers from the field of dementia care, including Dr. Jill Rasmussen, Primary Care Specialist in dementia, mental health, and intellectual disabilities; Delia Bashara, Consultant Pharmacist for the Mental Health of Older Adults and Dementia at South London and Maudsley NHS Foundation Trust; and Khaleel Loonat, Senior Clinical Pharmacist and Advanced Clinical Practitioner.

Alliance Healthcare UK team members Nick Atkins, Swansea Service Centre Manager, and Karl Goodall, Swansea Driver Team Manager, have climbed Pen y Fan in South Wales to support the Alzheimer's Society and raise money for dementia. The pair raised over £1,500, a cause close to Nick's heart, as his mother is a dementia patient. Dementia mainly affects people aged 65 and over, with 65 per cent of the 944,000 individuals living with dementia in the UK being women. Nick and Karl, dressed as 'glamorous grannies' with wigs, tights, and dresses, completed the mountain trek in six hours, carrying an Alliance Healthcare medicines cool box weighing over 35 kg. Alzheimer's Society supports people with dementia and their carers through national care and research efforts. Alzheimer's Society Cymru is the sole UK dementia charity funding both biomedical and care research.

A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer's disease. The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said. Alzheimer's Research UK, the Alzheimer's Society and the National Institute of Health and Care Research have jointly launched the project. Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK, said that the NHS doesn't possess the "required levels of diagnostic infrastructure" to cope with the "growing demand" for dementia diagnosis. "Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this," she added.

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease.